Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Study To Evaluate The Safety Of Combining IGF-1R Antagonist R1507 With Multiple Standard Chemotherapy Drug Treatments In Patients With Advanced Malignancies

Trial Profile

Phase Ib Study To Evaluate The Safety Of Combining IGF-1R Antagonist R1507 With Multiple Standard Chemotherapy Drug Treatments In Patients With Advanced Malignancies

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teprotumumab (Primary) ; Bevacizumab; Capecitabine; Carboplatin; Cetuximab; Docetaxel; Erlotinib; Etoposide; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel; Pemetrexed; Sorafenib; Temozolomide; Trastuzumab
  • Indications Breast cancer; Colon cancer; Lung cancer; Pancreatic cancer; Renal cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 09 Dec 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 04 Jun 2013 Trial was terminated early due to discontinued development of R1507, according to ASCO 2013 abstract.
    • 04 Jun 2013 Results were presented at 49th Annual Meeting of the American Society of Clinical Oncology (ASCO 2013).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top